studies

breast cancer - HER2-positive, afatinib plus vinorelbine vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsLUX-Breast 1, 2016 1.48 [1.12; 1.95] 1.48[1.12; 1.95]LUX-Breast 1, 201610%508NAnot evaluable progression or deaths (PFS)detailed resultsLUX-Breast 1, 2016 1.10 [0.86; 1.41] 1.10[0.86; 1.41]LUX-Breast 1, 201610%508NAnot evaluable objective responses (ORR)detailed resultsLUX-Breast 1, 2016 1.04 [0.71; 1.52] 1.04[0.71; 1.52]LUX-Breast 1, 201610%502NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-17 22:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1321

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons